Investor Relations

Latest News

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Mineralys Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Event icon

Coporate Presentation

Mineralys Corporate Overview June 2024

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

Mineralys Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company committed to developing treatments for diseases that are driven by abnormally elevated aldosterone. The Company’s clinical-stage product candidate, lorundrostat, is a highly selective aldosterone synthase inhibitor, licensed from Mitsubishi Tanabe Pharma Corporation (“Mitsubishi Tanabe”), that is being investigated for the treatment of hypertension. The Company has completed a Phase 2 proof-of-concept study in patients with uncontrolled hypertension and has plans for the continued research and development of lorundrostat in hypertension and other potential indications. The Company was incorporated as a Delaware corporation in May 2019, and it is headquartered in Radnor, Pennsylvania.

Stock Snapshot

Contact Information


Mineralys Therapeutics, Inc.
150 N. Radnor Chester Rd
Suite F200
Radnor, PA 19087
United States
Toll-Free: 888-378-6240

Transfer Agent

American Stock Transfer & Trust Company LLC
6201 15th Avenue
Brooklyn, New York 11219
United States
T: 800-937-5449
F: 718-236-2641


Elixir Health Public Relations
Tom Weible
T: 515-707-9678

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.